Keyphrases
A1 Receptor
100%
Glucagon-like
100%
Receptor Agonist
100%
Dipeptidyl peptidase-4 (DPP-4)
100%
Cost-effectiveness
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Antidiabetic Drugs
100%
New Antidiabetic Drugs
89%
Diabetes Model
30%
Insulin
30%
Cochrane
30%
Sulfonylurea
30%
Medical Subject Headings (MeSH)
20%
Reporting Quality
20%
Cost-effectiveness Analysis
20%
Economic Evaluation
20%
Health Economic Evaluation
20%
Reporting Standards
20%
Cost-effectiveness Study
20%
Thiazolidinediones
20%
Inclusion Criteria
10%
Embase
10%
PubMed
10%
MEDLINE
10%
Data Extraction
10%
Payer Perspective
10%
Good Quality
10%
CINAHL
10%
Search Strategy
10%
Pharmaceutical Companies
10%
Diabetes Type 1
10%
Cost-utility
10%
Technology Assessment
10%
Cost Reporting
10%
Antidiabetic Agents
10%
Registry Database
10%
Text Publication
10%
Evaluation Database
10%
Medicine and Dentistry
Systematic Review
100%
Cost-Effectiveness Analysis
100%
Glucagon-Like Peptide-1 Agonist
100%
Antidiabetic Agent
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Dipeptidyl Peptidase-4 Inhibitor
100%
Drug Therapy
90%
Health Care Cost
36%
Diabetes
27%
Sulfonylurea
27%
Effectiveness Study
18%
Thiazolidinedione
18%
Technology Assessment
9%
Neuroscience
Glucagon-Like Peptide-1 Agonist
100%
Sulfonylurea
100%
Dipeptidyl Peptidase-4 Inhibitor
100%
Sodium Glucose Cotransporter 2
100%
Thiazolidinedione
66%
Pharmacology, Toxicology and Pharmaceutical Science
Glucagon Like Peptide 1 Receptor Agonist
100%
Dipeptidyl Peptidase IV Inhibitor
100%
Antidiabetic Agent
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Sulfonylurea
27%
Effectiveness Study
18%
Thiazolidinedione
18%